News | Patient Monitors | September 09, 2015

Simple Test Predicts Obstructive Sleep Apnea in Hospitalized Heart Failure Patients

Overnight pulse-oximetry correlates with outpatient polysomnography

sleep apnea, pulse oximetery, congestive heart failure, CHF, pulse-oximetry, Thomas Jefferson University

September 9, 2015 — Researchers at Thomas Jefferson University showed that a simple questionnaire, evaluation and pulse-oximetry monitoring can lead to early detection of sleep apnea in patients hospitalized for congestive heart failure (CHF). The results were published in the Journal of American College of Cardiology: Heart Failure.

“Since traditional screenings are not always effective in patients with congestive heart failure, additional tools are needed,” said lead author Sunil Sharma, M.D., FAASM, associate professor of pulmonary medicine in the Sidney Kimmel Medical College at Thomas Jefferson University. “Our team was able to validate a screening strategy that can be instituted during hospitalization and effectively detect sleep disordered breathing among patients with congestive heart failure.”

This study adds to a growing body of research suggesting a connection between sleep disordered breathing and heart failure. “While an estimated 70 percent of patients with congestive heart failure have underlying sleep disordered breathing, only a minority, roughly 2 percent, are diagnosed and treated. Yet early recognition and treatment of this disorder in patients with congestive heart failure has been shown to improve ejection fraction, acute heart failure and may even reduce readmissions and mortality,” Sharma continued.

Consecutive patients admitted for congestive heart failure at Thomas Jefferson University Hospital were screened by respiratory therapists using the STOP-BANG Questionnaire (Snoring, Tiredness during daytime, Observed apnea, high blood Pressure – Body mass index greater than 35, Age greater than 50 years, Neck circumference greater than 40 centimeters and Male gender).

If the patient screened positive, they received a formal sleep consult during their hospital stay and underwent high-resolution pulse-oximetry testing, which assessed the patient’s oxygen desaturation index (ODI). This low-cost device measures how much oxygen is in a patient’s blood. Researchers hypothesized that dips in oxygen levels throughout the night were a sign of obstructive sleep apnea.

Patients with a high ODI were recommended to undergo overnight polysomnography as an outpatient. Of those who followed up with the recommended polysomnography (n=68), 94 percent (n=64) were diagnosed with sleep disordered breathing.

“Patients with congestive heart failure do not always present with traditional symptoms of sleep apnea, like daytime sleepiness and heavy snoring,” said Paul J. Mather, M.D., FACC, FACP, Lubert Family Professor of Cardiology in the Sidney Kimmel Medical College at Thomas Jefferson University and director of the Advanced Heart Failure and Cardiac Transplant Center at the Jefferson Heart Institute. “This study presents cardiologists with a cost-effective clinical pathway to detect sleep disordered breathing while these patients are hospitalized.”

“Our team’s research showed that overnight pulse-oximetry, a simple low cost device used in the hospital setting, correlates well with the gold-standard polysomnography,” said David J. Whellan, M.D., MHS, FACC, FAHA, the James C. Wilson Professor of Medicine in the Sidney Kimmel Medical College at Thomas Jefferson University and senior author on the study. “Future research is need to see if early screening and intervention of sleep disorder breathing, specifically obstructive sleep apnea, can reduce readmissions, morbidity and mortality in patients with congestive heart failure.”

For more information: www.jefferson.edu

Related Content

 Revivant TC
News | Heart Failure | December 18, 2019
December 18, 2019 — BioVentrix, Inc., developer of the first less
 impulse dynamics Optimizer for Heart failure.
News | Heart Failure | December 12, 2019
December 12, 2019 — Impulse Dynamics, developer of Optimizer Smart System
The Cordella Pulmonary Artery Pressure Sensor System for Heart failure. #AHA19 #AHA
News | Heart Failure | November 21, 2019
November 21, 2019 — Endotronix, a digital health and medical technology company dedicated to advancing the treatment
Heart failure VICTORIA TrIal a success. Dave Fornell
News | Heart Failure | November 21, 2019
November 21, 2019 — Merck announced the results from the Phase 3 VICTORIA Study evaluating the efficacy and safety of
The U.S. Food and Drug Administration (FDA) has granted market clearance for AstraZeneca's dapagliflozin (Farxiga) to reduce the risk of hospitalization for heart failure (HF) in adults with type 2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors.
Feature | Heart Failure | October 21, 2019 | Dave Fornell, Editor
October 21, 2019 – The U.S.
Research Shows Drug Can Extend Survival Rates for Heart Failure Patients
News | Heart Failure | October 16, 2019
Researchers have shown for the first time in preclinical studies that the drug Aliskiren can delay the progression of...
The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms. #TMVR #TCT2019 #TCT19

The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms.

News | Heart Failure | October 04, 2019
October 4, 2019 – Results of a new economic analysis of the COAPT Trial data found that transcatheter mitral valve re
COAPT Trial three-year data show the MitraClip continued effectiveness in heart failure patients with secondary mitral reguritation. #TCT2019 #TCT19 #mitralclip

COAPT Trial three-year data show the MitraClip continues to show safety and effectiveness in heart failure patients with secondary mitral reguritation.

News | Heart Failure | October 03, 2019
October 3, 2019 – The three-year results from the...
Positive Safety, Efficacy Data Reported on AccuCinch Heart Failure Device
News | Heart Failure | September 27, 2019
Ancora Heart Inc. announced results from an interim analysis of heart failure patients treated in the CorCinch FMR...
Max and Debra Ernst Heart Center Opening at Beaumont Hospital, Royal Oak
News | Heart Failure | September 20, 2019
The new Max and Debra Ernst Heart Center at Beaumont Hospital, Royal Oak, Mich., will open Sept. 30. It is dedicated to...
Overlay Init